Genmab — September 2024

[E_L]

Stephen V Liu, MD
@StephenVLiu
Oral session at #WCLC24 on targeted therapy chaired by Drs.
@drprunellab

@LeXiuning
starts with Dr.
@ShirishGadgeel
with an update on MARIPOSA https://x.com/StephenVLiu/status/1832842542158901496

[Helge_LarsenPI-redaktør]

Thanks E L.

[GeorgeBest]

I thought the nice Rybrevant data could give us a good upward move today. But it shouldn’t be so…

[E_L]

ESMO24 - 719MO - A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/presentation/list?q=719MO+

[E_L]

so, In Part B, ORR for ovarian cancer pts randomized and treated at 120 mg/m2 was 50% (6/12 pts)

[Darvin]

Agree
GB. Perhaps the investors are not paying close attention to Genmab at the moment, and have directed their attention elsewhere. The stock should go up, not down.

[E_L]

it is no fun taking this drug looking at the treatment-related adverse events , but they call it 'manageable TRAEs'. Fortunately no ocular toxicity or interstitial lung disease

[E_L]

There has been a lot of positive news on Rybrevant, Teclistamab, Talquetamab, even Dara over the last few months, but is has all been neglected. I don't even bother posting most of it anymore...

[Darvin]

Please do

[E_L]

Cancer drug offers life-changing results for severe lupus patient - teclistamab - https://www.news-medical.net/news/20240906/Cancer-drug-offers-life-changing-results-for-severe-lupus-patient.aspx

[E_L]

Amivantamab at ESMO -
https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/presentation/list?q=Amivantamab+

[lahn1]

First glance seem Rina-S ORR a bit lower than at SITC, but nice 50% at 120mg (MTD 140mg), lots af AE. This must be the data that convinced Gmab take over profound ? beside linker ect

[E_L]

this is the data they saw when buying Profound at Apr3, data cut off is Apr2. So they had clear inside on this AE profile and deemed it safe enough to buy. I think that is a big +

[Raun]

Tror bare vi skal væbne os med tålmodighed - belønnigen komme inden så længe føler jeg mig ret så sikker på..... Det er latterlig lav omsætninger vi har set den seneste tid - så det som tidligere nævnt stilstand før storm...

[E_L]

Truist sees Genmab stock undervalued despite strong pipeline potential https://www.investing.com/news/company-news/truist-sees-genmab-stock-undervalued-despite-strong-pipeline-potential-93CH-3606894

[Solsen]

The lupus pts is fantastic. Lupus is bad to have.

[Hugininvest]

Der er i hvert fald nogle der ikke kan “regne den ud”, er min salige påstand. Upside potentiale lige nu, er langt langt højere end downside risiko. Det er da fint, hvis man regner med at købe på et mindre dyk, men ikke sikkert det lykkes, og slet slet ikke sikkert det kommer. Upside derimod er nærmest sikker. Usikkerheden er blot hvornår. Det er altså nu man skal købe. Analytikerne kommer altid på bagkant, så vent ikke på dem.

[Solsen]

Compare the Amivantamab combo against Tagrisso alone in naive NCSCL pts is not the right comparison. Tagrisso plus Chemo are more realistic https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-the-eu-as-new-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.html

[Solsen]

It explains why market isnt rewarding Genmab.

[Solsen]

But the Lupus story is very interesting. I belive the CD38 target has lot of potential outside cancers.